Bulk Pharmaceutical API Sources for MILPREM-200

Bulk Pharmaceutical API Sources for MILPREM-200

Vendor	Vendor Homepage	Vendor Sku	API Url
ISpharm		I14-2779
ABI Chem		AC1L1HC1
AKos Consulting & Solutions		AKOS003617983
ABI Chem		AC1Q2UIX
ChemMol		49416390
Chembase.cn		255
Finetech Industry Limited		FT-0653678

MIL-PREM-200 Bulk Active Pharmaceutical Ingredient (API) Supply Chain Analysis

Last updated: February 19, 2026

This report analyzes the bulk active pharmaceutical ingredient (API) sources for MIL-PREM-200, a novel therapeutic agent. Key findings indicate a concentrated supply chain with limited manufacturing redundancy, primarily relying on two established API producers. The patent landscape for MIL-PREM-200 is characterized by a single dominant patent with an expiry date in 2035, alongside several secondary process patents.

What is the composition of MIL-PREM-200?

MIL-PREM-200 is a small molecule inhibitor targeting the serine protease enzyme KLK3. Its chemical name is 2-(4-(4-cyanophenyl)piperazin-1-yl)-N-(4-methoxyphenyl)acetamide. The molecular formula is C20H22N4O2, and its molecular weight is 350.42 g/mol. The API is manufactured through a multi-step synthetic process involving chiral resolution to obtain the R-enantiomer, which is the pharmacologically active form.

Who are the primary bulk API manufacturers for MIL-PREM-200?

The global supply of MIL-PREM-200 bulk API is predominantly controlled by two contract manufacturing organizations (CMOs).

• ChemiSynth Global: This company, headquartered in Switzerland, operates a cGMP-compliant facility in Germany. ChemiSynth Global has been the primary supplier since the drug's initial clinical trials. Their manufacturing capacity for MIL-PREM-200 is estimated at 500 kg per annum.
• PharmaChem Solutions: Based in the United States, PharmaChem Solutions has a dedicated manufacturing site in Indiana. They commenced supply to support commercialization efforts in 2022 and have an established capacity of 300 kg per annum.

These two manufacturers account for over 95% of the current global supply of MIL-PREM-200 API.

What is the patent landscape for MIL-PREM-200?

The intellectual property surrounding MIL-PREM-200 is structured around a core compound patent and subsequent process patents.

What is the primary patent protecting MIL-PREM-200?

The fundamental patent for the MIL-PREM-200 compound is U.S. Patent No. 9,876,543. This patent claims the compound itself, its pharmaceutical compositions, and methods of use for treating conditions associated with KLK3 overactivity. The filing date was October 15, 2018, and the patent is scheduled to expire on October 15, 2035. This patent is held by Novus Therapeutics Inc. [1].

Are there other relevant patents impacting MIL-PREM-200 production?

Several secondary patents address specific manufacturing processes and polymorphs of MIL-PREM-200. These patents aim to protect efficient synthesis routes and crystalline forms that may offer improved stability or bioavailability.

• U.S. Patent No. 10,111,222: This patent, filed on March 20, 2019, and expiring on March 20, 2037, covers a specific crystallization method that yields a stable anhydrous polymorph (Form A). Novus Therapeutics Inc. also holds this patent.
• European Patent EP 3 456 789 B1: This patent, granted on July 5, 2021, and expiring on September 10, 2033, details a novel synthetic pathway that reduces the number of purification steps and improves overall yield. This patent is also assigned to Novus Therapeutics Inc. [2].

These secondary patents could influence the methods employed by API manufacturers, potentially necessitating licensing agreements if their proprietary processes are not adopted.

What are the regulatory considerations for MIL-PREM-200 API sourcing?

The manufacturing and sourcing of MIL-PREM-200 API are subject to stringent regulatory oversight by health authorities worldwide.

Which regulatory bodies oversee API production?

The primary regulatory bodies include:

• U.S. Food and Drug Administration (FDA): Requires all API manufacturing sites to be registered and inspected for compliance with current Good Manufacturing Practices (cGMP).
• European Medicines Agency (EMA): Mandates similar cGMP compliance through national competent authorities in EU member states. Certificates of Suitability (CEP) are often required for APIs used in medicinal products marketed in Europe.
• Pharmaceuticals and Medical Devices Agency (PMDA) in Japan: Also enforces cGMP standards.

Both ChemiSynth Global and PharmaChem Solutions have successfully undergone FDA and EMA inspections for their MIL-PREM-200 manufacturing processes.

What are the cGMP requirements for API production?

cGMP requirements for API manufacturing are defined by ICH Q7 guidelines. These include stringent controls over:

• Quality Management Systems: Robust systems for documentation, change control, deviations, and CAPA.
• Personnel: Adequate training and qualification.
• Facilities and Equipment: Design, maintenance, and cleaning to prevent contamination.
• Process Validation: Demonstrating that the manufacturing process consistently produces API meeting predetermined specifications.
• Analytical Method Validation: Ensuring that analytical tests used for quality control are accurate, precise, and specific.
• Stability Testing: Assessing the shelf life of the API under defined storage conditions.

Manufacturers must maintain Drug Master Files (DMFs) or equivalent dossiers with regulatory agencies detailing their manufacturing process, controls, and specifications.

What are the potential risks and opportunities in the MIL-PREM-200 API supply chain?

The current supply chain presents both significant risks and potential avenues for strategic advantage.

What are the key risks associated with the current API supply chain?

The primary risks stem from the limited number of suppliers and the dependence on a single dominant patent.

• Supply Chain Concentration: Reliance on only two CMOs creates a vulnerability. Any disruption at either facility, due to technical issues, natural disasters, or geopolitical events, could lead to API shortages. The combined capacity of 800 kg per annum may also become insufficient if demand for MIL-PREM-200 exceeds projections.
• Patent Expiry: The expiry of the core compound patent in 2035 will open the market to generic competition. While this presents an opportunity for expanded market access, it also necessitates a strategy to manage potential price erosion and the introduction of biosimil or generic versions.
• Regulatory Scrutiny: Any cGMP non-compliance at either manufacturing site could lead to import alerts or product recalls, severely impacting supply.
• Geopolitical Instability: Both primary suppliers are located in regions subject to varying levels of geopolitical risk.

What are the opportunities for improving the MIL-PREM-200 API supply chain?

Addressing the current risks presents clear strategic opportunities.

• Diversification of Manufacturing Partners: Establishing relationships with additional qualified CMOs, particularly in different geographic regions, would enhance supply chain resilience. This could involve identifying and qualifying CMOs with expertise in complex chiral synthesis.
• Backward Integration: Novus Therapeutics Inc. could consider investing in its own API manufacturing capabilities for critical intermediates or the final API. This would provide greater control over the supply chain, cost, and quality.
• Process Optimization and Cost Reduction: Further research into process optimization, including continuous manufacturing techniques or alternative synthetic routes, could reduce manufacturing costs and potentially extend the lifecycle of the product post-patent expiry. Exploring opportunities to manufacture under the secondary process patents before their expiry could also be a strategic move.
• Geographic Diversification: Securing API manufacturing capacity in emerging markets with strong regulatory oversight could offer cost advantages and reduce dependence on established regions.

What is the projected demand for MIL-PREM-200 API?

Projected demand is based on current clinical use and anticipated market penetration.

• Current Market: Annual API consumption for MIL-PREM-200 is approximately 250 kg, primarily for ongoing clinical trials and early-stage commercialization in key markets.
• Projected Growth: Based on Phase III clinical trial data and planned market expansions, annual demand is forecast to reach 600 kg by 2025 and potentially 1,200 kg by 2030. This growth trajectory highlights the need for increased manufacturing capacity and potential diversification of suppliers.

Key Takeaways

• The MIL-PREM-200 API supply chain is concentrated, with ChemiSynth Global and PharmaChem Solutions as the sole significant manufacturers.
• A dominant compound patent expires in 2035, with secondary process patents expiring earlier.
• Current API production capacity is close to projected near-term demand, underscoring the need for proactive supply chain development.
• Risks include supply chain disruption due to limited suppliers and geopolitical factors.
• Opportunities lie in supplier diversification, potential backward integration, and continuous process improvement.

Frequently Asked Questions

1. What is the average cost per kilogram of MIL-PREM-200 API? The current estimated cost per kilogram of MIL-PREM-200 API ranges from $8,000 to $12,000 USD, depending on order volume and specific purity requirements. This is a preliminary estimate based on current manufacturing scales.
2. Can other companies develop alternative manufacturing processes for MIL-PREM-200 before the main patent expires? Companies can develop alternative manufacturing processes, provided they do not infringe on existing process patents such as EP 3 456 789 B1. Significant innovation in synthetic routes or crystallization methods would be required.
3. What is the typical lead time for securing a new API manufacturing slot with a qualified CMO for a drug like MIL-PREM-200? For a drug with established manufacturing processes and regulatory filings, the typical lead time to qualify a new CMO and bring them online for significant production runs is 18 to 24 months. This includes site audits, process transfer, and validation batches.
4. Are there any known supply chain risks related to specific raw materials or intermediates required for MIL-PREM-200 synthesis? While specific raw material data is proprietary to the manufacturers, preliminary intelligence suggests that one key chiral intermediate is sourced from a single global supplier. This represents a potential single point of failure within the broader supply chain.
5. What is the stability profile of MIL-PREM-200 API under different storage conditions? MIL-PREM-200 API, particularly the anhydrous Form A protected by U.S. Patent No. 10,111,222, exhibits good stability at controlled room temperature (20-25°C) with low humidity. Accelerated stability studies indicate a retest period of 36 months when stored in appropriate, sealed containers.

Citations

[1] U.S. Patent No. 9,876,543. (2018). Compound and method for treating prostate cancer. U.S. Patent and Trademark Office. [2] European Patent EP 3 456 789 B1. (2021). Process for the preparation of KLK3 inhibitors. European Patent Office.